Agenda
Breast cancer
Advanced HER2-positive/HER2-low breast cancer
Patient with brain metastasis and stable extracranial disease: when to change antiHER2-based therapy
Patient with active brain metastasis: locoregional therapy vs systemic therapy
Patient with active brain metastasis: T-DXd vs.
tucatinib-based therapy
Can we use TDM1 after T-DXd
Role of repeated biopsies to guide ADCs in HER2-low BC
Moderator: 
Shereef Elsamany
Panel:
Dr. Hamdi Abdelazim
Dr. Ahmed Alfaraj
Dr. Ahmed Saadeldine
Dr. Aboelkhair Algahami
Dr. Abdullah Altwergi
Dr. Shadi Khayat
Dr. Essam Murshid
Dr. Adher Elsayed
Dr. Bassam Basulaiman
Prof. Yasir Bahader
Role of anthracyclines in early breast cancer
- When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer
When to use anthracyclines in (neo) adjuvant therapy of HER2-positive breast cancer
Moderator:
Dr. Meteeb Alfohaidi
Panel:
Dr. Ahmed Alfaraj
Dr. Om Alkhair Aboelkhair
Dr. Ahmed Alshehri
Dr. Ahmed Alwabari
Dr. Maged Aljahel
Dr. Taleb Bouhleeqa
Dr. Abdelrahman Alshehri
Dr. Ibrahim Madkhali
Dr. Emad Dawoud
Satellite Symposium
Can we de-escalate axillary surgery/omit adjuvant radiotherapy with excellent response after NAC?
Complete response to NAC
Residual ITCs after NAC
Controversies of targeted axillary dissection
SLNB: Negative LNs in frozen section/positive in final pathology
Negative SLNB after neoadjuvant hormonal therapy
Moderator:
Dr. Nasser Ali Al-Dhaibani 
Dr. Roaa Attieh
Panel:
Dr. Maha Alidrisi
Prof. Yasir Bahader
Dr. Mariam Alsulami
Dr. Emad Elshareef
Dr. Adher Elsayed
Dr. Ahmed Alrefaei
Dr. Mohamed Aseafan
Opening ceremony
Lunch & prayer
Satellite Symposium
Oncologists/pathologists dialogue TILS and descalation of systemic therapy in early breast cancer?
Moderator: 
Dr. Ahmed Alwbari 
Dr. Hatim Al Maghrabi
Prof. Alaa Kandil
Dr. Meteb Alfoheidi
Dr. Fadi Farhat
Dr. Zuhair Elkhair Ahmed Alzubair
Dr. Nasr Al-lahloubi
Dr. Bassam Basulaiman
Genomic tools in breast cancer
- chemotherapy in high risk lobular/mucinous BC?
- Neoadjuvant therapy in premenopausal patients with lobular BC?
Adjuvant therapy with node negative and node positive lobular BC?
Adjuvant therapy in luminal BC with RS 16-25?
Can genomic tools guide adjuvant cdk4-6 inhibitors in N0/N1 tumours?? - Oncotype DX and selection of neoadjuvant hormonal vs chemotherapy therapy
- Role of interval Ki67 assessment with neoadjuvant hormonal therapy
Moderator: 
Ahmed Alshehri
Panel:
Dr. Hamdi Abdelazim
Dr. Adher Elsayed
Dr. Om Alkhair Aboelkhair
Dr. Abdullah Altwergi
Dr. Ahmed Zeeneldine
Dr. omaima Elemam
Dr. Ahmed Alwabari
Dr. Nasr Al-lahloubi
Dr. Ibrahim Madkhali
Break
Transition from hormonal-based to chemotherapy in metastatic BC??
- Patients with early progression on CDK4-6 inhibitors: What is next??
- When to start ADCs/olaparib in patients who had visceral crisis?? Can be upfront??
- Any role of hormonal monotherapy after CDK4-6 inhibitors??
- Biomarkers to guide subsequent therapies
- Can we use one ADC after previous ADC??
Moderator: 
Dr. Ahmed Alfaraj
Panel:
Dr. Nasr Al-lahloubi
Dr. Meteb Alfoheidi
Prof. Alaa Kandil
Dr. Ahmed Saadeldine
Dr. Fadi Farhat
Dr. Sherif Kullab
Dr. Maged Aljahel
Dr. Nafisa Abdelhafeez
Dr. Ehab Elnakouri
Dr. Mohamed Aseafan
Concluding remarks Day 1
Setting-up clinical trials in Middle east: Challenges and opportunities
Moderators:
Dr. Emad Tashkandi 
Dr. Hosam Alghanmi
Panel:
Dr. Ali Aljubran
Dr. Mervat Mahrous
Dr. Marwan Alhejeeli
Dr. Atlal Abusanad
Dr. Mohamed Algarni
Pancreatic cancer
- Neoadjuvant therapy in resectable/borderline resectable pancreatic cancer
- Best neoadjuvant strategy
- 1st line and subsequent therapies in pancreatic cancer: Doublet vs Triplets
- biomarkers for metastatic patients
Moderator: 
Dr. Abdullah Alsharm
Panel:
Prof. Dirk Arnold
Dr. Ashwaq Alolayan
Dr. Samah Alraheli
Dr. Ahmed Allehebi
Dr. Abdulsalam Alnajar
Dr. Waleed Selwi
Dr. Emad Dawoud
Dr. Ali Alqahtani
Biliary tract cancer
- Immunetherapy in advanced BTC: Yes/No
- Which agent?
- Patient selection/tumour location?
- Role of maintenance therapy?
- Role of liquid biopsy/biomarker assessment
Moderator: 
Dr. Mohammed Algarni
panel:
Dr. Ashwaq Alolayan
Dr. Fahed Ibn Shamsa
Dr. Kanan Alshammari
Dr. Mervat Mahrous
Dr. Kakil Rasul
Dr. Ali Alfakeeh
Dr. Nedal Bukhari
Dr. Marwan Alhejeeli
Break
Perioperative therapy in Gastric cancer
- Role of laparoscopy assessment before perioperative therapy?
- What to do in patients with poor response to neoadjuvant therapy?
- Role of biomarkers e.g MSI in decision-making before perioperative therapy?
- Patients with limited peritoneal metastasis: Role of HIPEC?
- Role of immunetherapy with perioperative therapy non-metastatic gastric cancer?
Moderator: 
Dr. Fahad Ibnshamsah
Prof. Dirk Arnold
Dr. Nedal Bukhari
Dr. Samah Alraheli
Dr. Ali Alqahtani
Dr. Emad Tashkandi
Dr. Waleed Selwi
Dr. Ali Alfakeeh
Dr. Ali Aljubran
Dr. Kanan Alshammari
Challenges and dynamics of oncology health care
- Financial toxicities and economic burden
- Delayed access to oncology care
- Cancer survivors: challenges and special requirements
- Integration of service with primary health care for cancer survivors
Moderator: 
Dr. Esam Murshid
Panel:
Dr. Abdullah Alsharm
Dr. Ahmed Alrefaei
Dr. Yousry Rostom
Dr. Kakil Rasul
Dr. Sakher Abdullah
Dr. Hani Elkhatib
Dr. Abdulsalam Alnajar
Dr. Emad Dawoud
Dr. Atlal Abusanad
Dr. Ahmed Allehebi
Immunetherapy in CRC: Transition from metastatic to early stage
Prof. Dirk Arnold
Satellite Symposium
Closing remarks
Prayer &Lunch
Breast cancer
Advanced HER2-positive/HER2-low breast cancer
Patient with brain metastasis and stable extracranial disease: when to change antiHER2-based therapy
Patient with active brain metastasis: locoregional therapy vs systemic therapy
Patient with active brain metastasis: T-DXd vs.
tucatinib-based therapy
Can we use TDM1 after T-DXd
Role of repeated biopsies to guide ADCs in HER2-low BC
Moderator: Shereef Elsamany
Panel:
Dr. Hamdi Abdelazim
Dr. Ahmed Alfaraj
Dr. Ahmed Saadeldine
Dr. Aboelkhair Algahami
Dr. Abdullah Altwergi
Dr. Shadi Khayat
Dr. Essam Murshid
Dr. Adher Elsayed
Dr. Bassam Basulaiman
Prof. Yasir Bahader
Role of anthracyclines in early breast cancer
- When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer
When to use anthracyclines in (neo) adjuvant therapy of HER2-positive breast cancer
Moderator:Dr. Meteeb Alfohaidi
Panel:
Dr. Ahmed Alfaraj
Dr. Om Alkhair Aboelkhair
Dr. Ahmed Alshehri
Dr. Ahmed Alwabari
Dr. Maged Aljahel
Dr. Taleb Bouhleeqa
Dr. Abdelrahman Alshehri
Dr. Ibrahim Madkhali
Dr. Emad Dawoud
Satellite Symposium
Can we de-escalate axillary surgery/omit adjuvant radiotherapy with excellent response after NAC?
Complete response to NAC
Residual ITCs after NAC
Controversies of targeted axillary dissection
SLNB: Negative LNs in frozen section/positive in final pathology
Negative SLNB after neoadjuvant hormonal therapy
Moderator:Dr. Nasser Ali Al-Dhaibani Dr. Roaa Attieh
Panel:
Dr. Maha Alidrisi
Prof. Yasir Bahader
Dr. Mariam Alsulami
Dr. Emad Elshareef
Dr. Adher Elsayed
Dr. Ahmed Alrefaei
Dr. Mohamed Aseafan
Opening ceremony
Lunch & prayer
Satellite Symposium
Oncologists/pathologists dialogue TILS and descalation of systemic therapy in early breast cancer?
Moderator: Dr. Ahmed Alwbari Dr. Hatim Al Maghrabi
Prof. Alaa Kandil
Dr. Meteb Alfoheidi
Dr. Fadi Farhat
Dr. Zuhair Elkhair Ahmed Alzubair
Dr. Nasr Al-lahloubi
Dr. Bassam Basulaiman
Genomic tools in breast cancer
- chemotherapy in high risk lobular/mucinous BC?
- Neoadjuvant therapy in premenopausal patients with lobular BC?
Adjuvant therapy with node negative and node positive lobular BC?
Adjuvant therapy in luminal BC with RS 16-25?
Can genomic tools guide adjuvant cdk4-6 inhibitors in N0/N1 tumours?? - Oncotype DX and selection of neoadjuvant hormonal vs chemotherapy therapy
- Role of interval Ki67 assessment with neoadjuvant hormonal therapy
Moderator: Ahmed Alshehri
Panel:
Dr. Hamdi Abdelazim
Dr. Adher Elsayed
Dr. Om Alkhair Aboelkhair
Dr. Abdullah Altwergi
Dr. Ahmed Zeeneldine
Dr. omaima Elemam
Dr. Ahmed Alwabari
Dr. Nasr Al-lahloubi
Dr. Ibrahim Madkhali
Break
Transition from hormonal-based to chemotherapy in metastatic BC??
- Patients with early progression on CDK4-6 inhibitors: What is next??
- When to start ADCs/olaparib in patients who had visceral crisis?? Can be upfront??
- Any role of hormonal monotherapy after CDK4-6 inhibitors??
- Biomarkers to guide subsequent therapies
- Can we use one ADC after previous ADC??
Moderator: Dr. Ahmed Alfaraj
Panel:
Dr. Nasr Al-lahloubi
Dr. Meteb Alfoheidi
Prof. Alaa Kandil
Dr. Ahmed Saadeldine
Dr. Fadi Farhat
Dr. Sherif Kullab
Dr. Maged Aljahel
Dr. Nafisa Abdelhafeez
Dr. Ehab Elnakouri
Dr. Mohamed Aseafan
Concluding remarks Day 1
Setting-up clinical trials in Middle east: Challenges and opportunities
Moderators:
Dr. Emad Tashkandi Dr. Hosam Alghanmi
Panel:
Dr. Ali Aljubran
Dr. Mervat Mahrous
Dr. Marwan Alhejeeli
Dr. Atlal Abusanad
Dr. Mohamed Algarni
Pancreatic cancer
- Neoadjuvant therapy in resectable/borderline resectable pancreatic cancer
- Best neoadjuvant strategy
- 1st line and subsequent therapies in pancreatic cancer: Doublet vs Triplets
- biomarkers for metastatic patients
Moderator: Dr. Abdullah Alsharm
Panel:
Prof. Dirk Arnold
Dr. Ashwaq Alolayan
Dr. Samah Alraheli
Dr. Ahmed Allehebi
Dr. Abdulsalam Alnajar
Dr. Waleed Selwi
Dr. Emad Dawoud
Dr. Ali Alqahtani
Biliary tract cancer
- Immunetherapy in advanced BTC: Yes/No
- Which agent?
- Patient selection/tumour location?
- Role of maintenance therapy?
- Role of liquid biopsy/biomarker assessment
Moderator: Dr. Mohammed Algarni
panel:
Dr. Ashwaq Alolayan
Dr. Fahed Ibn Shamsa
Dr. Kanan Alshammari
Dr. Mervat Mahrous
Dr. Kakil Rasul
Dr. Ali Alfakeeh
Dr. Nedal Bukhari
Dr. Marwan Alhejeeli
Break
Perioperative therapy in Gastric cancer
- Role of laparoscopy assessment before perioperative therapy?
- What to do in patients with poor response to neoadjuvant therapy?
- Role of biomarkers e.g MSI in decision-making before perioperative therapy?
- Patients with limited peritoneal metastasis: Role of HIPEC?
- Role of immunetherapy with perioperative therapy non-metastatic gastric cancer?
Moderator: Dr. Fahad Ibnshamsah
Prof. Dirk Arnold
Dr. Nedal Bukhari
Dr. Samah Alraheli
Dr. Ali Alqahtani
Dr. Emad Tashkandi
Dr. Waleed Selwi
Dr. Ali Alfakeeh
Dr. Ali Aljubran
Dr. Kanan Alshammari
Challenges and dynamics of oncology health care
- Financial toxicities and economic burden
- Delayed access to oncology care
- Cancer survivors: challenges and special requirements
- Integration of service with primary health care for cancer survivors
Moderator: Dr. Esam Murshid
Panel:
Dr. Abdullah Alsharm
Dr. Ahmed Alrefaei
Dr. Yousry Rostom
Dr. Kakil Rasul
Dr. Sakher Abdullah
Dr. Hani Elkhatib
Dr. Abdulsalam Alnajar
Dr. Emad Dawoud
Dr. Atlal Abusanad
Dr. Ahmed Allehebi
Immunetherapy in CRC: Transition from metastatic to early stage
Prof. Dirk Arnold
Satellite Symposium
Closing remarks
Prayer &Lunch
